Diabetic retinopathy - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Diabetic retinopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic retinopathy: Overview
Diabetic retinopathy is a serious sight-threatening complication of diabetes. Diabetes interferes with the body's ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Over time, diabetes damages small blood vessels throughout the body, including the retina. Diabetic retinopathy occurs when these tiny blood vessels leak blood and other fluids. This causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop diabetic retinopathy. If left untreated, diabetic retinopathy can cause blindness. When people with diabetes experience long periods of high blood sugar, fluid can accumulate in the lens inside the eye that controls focusing. This changes the curvature of the lens, leading to changes in vision. However, once blood sugar levels are controlled, usually the lens will return to its original shape and vision improves. Patients with diabetes who can better control their blood sugar levels will slow the onset and progression of diabetic retinopathy.
'Diabetic retinopathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic retinopathy pipeline landscape is provided which includes the disease overview and Diabetic retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic retinopathy Emerging Drugs
Further product details are provided in the report……..
Diabetic retinopathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic retinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic retinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic retinopathy drugs.
Diabetic retinopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diabetic retinopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic retinopathy: Overview
Diabetic retinopathy is a serious sight-threatening complication of diabetes. Diabetes interferes with the body's ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Over time, diabetes damages small blood vessels throughout the body, including the retina. Diabetic retinopathy occurs when these tiny blood vessels leak blood and other fluids. This causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop diabetic retinopathy. If left untreated, diabetic retinopathy can cause blindness. When people with diabetes experience long periods of high blood sugar, fluid can accumulate in the lens inside the eye that controls focusing. This changes the curvature of the lens, leading to changes in vision. However, once blood sugar levels are controlled, usually the lens will return to its original shape and vision improves. Patients with diabetes who can better control their blood sugar levels will slow the onset and progression of diabetic retinopathy.
'Diabetic retinopathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic retinopathy pipeline landscape is provided which includes the disease overview and Diabetic retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic retinopathy.
This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic retinopathy Emerging Drugs
- Brolucizumab: Novartis
- RGX 314: Regenxbio Inc.
Further product details are provided in the report……..
Diabetic retinopathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic retinopathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Diabetic retinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic retinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic retinopathy drugs.
Diabetic retinopathy Report Insights
- Diabetic retinopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic retinopathy drugs?
- How many Diabetic retinopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic retinopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic retinopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic retinopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Regenxbio Inc.
- Boehringer Ingelheim
- Bayer
- RemeGen Co., Ltd.
- Kubota Vision
- Hoffmann-La Roche
- Allegro Ophthalmics
- MingSight Pharmaceuticals
- Ocuphire Pharma, Inc.
- Adverum Biotechnologies, Inc.
- Applied Therapeutics
- OcuNexus Therapeutics
- Alcon
- Aerpio Pharmaceuticals
- EyeGene
- Aerie Pharmaceuticals
- OccuRx
- NovaGo Therapeutics
- HanAll Biopharma
- Ascentage Pharma
- AptaBio
- BONAC corporation
- CCRP Therapeutics
- Curacle Co Ltd
- Emerald Bioscience, Inc.
- EnnovaBio
- Everglades Biopharma
- Excitant Therapeutics, LLC
- Foresee Pharmaceuticals Co., Ltd.
- Glycadia
- Hengenix Biotech Inc
- Kubota Vision Inc.
- LUYE PHARMA
- MIRAE CELL BIO
- Novelty Nobility Inc
- Noveome Biotherapeutics, Inc.
- OliPass Corporation
- Palatin Technologies Inc
- PharmAbcine Inc
- PYC Therapeutics
- Retinset SL
- RIBOMIC
- Brolucizumab
- RGX 314
- BI 764524
- Runcaciguat
- RC28-E
- emixustat hydrochloride
- RG7774
- Luminate
- MS-553
- APX3330
- ADVM-022
- AT 003
- HCB 1019
- Nepafenac
- Razuprotafib
- EGT 022
- OCX-063
- NG 004
- HL 190
- UBX 1967
- APX-1004
- BNC-1601
- CU06
- FP-008
- GLY 230
- HLX04
- Emixustat HCI
- LY09004
- NN2101
- PMC-403
- PYC-001
- BSL01
- RBM-008
Introduction
Executive Summary
Diabetic retinopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Brolucizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RGX 314: Regenxbio Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY09004: Luye Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PYC-001: PYC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Diabetic retinopathy Key Companies
Diabetic retinopathy Key Products
Diabetic retinopathy- Unmet Needs
Diabetic retinopathy- Market Drivers and Barriers
Diabetic retinopathy- Future Perspectives and Conclusion
Diabetic retinopathy Analyst Views
Diabetic retinopathy Key Companies
Appendix
Executive Summary
Diabetic retinopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Brolucizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RGX 314: Regenxbio Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY09004: Luye Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PYC-001: PYC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Diabetic retinopathy Key Companies
Diabetic retinopathy Key Products
Diabetic retinopathy- Unmet Needs
Diabetic retinopathy- Market Drivers and Barriers
Diabetic retinopathy- Future Perspectives and Conclusion
Diabetic retinopathy Analyst Views
Diabetic retinopathy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Diabetic retinopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Diabetic retinopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Diabetic retinopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Diabetic retinopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
